Areas of Interest
The Fry laboratory is working to gain a better understanding of synaptic neurochemical markers in the brain, and to advance the field of neuroimaging. The ultimate goal is to generate direct imaging measures of the effects of diseases and therapies in the human brain in order to advance our understanding of neurologic and psychiatric illness and support the development of more effective therapies.
Frey’s lab is actively pursuing two separate but interrelated research tracks:
1. The development and characterization of markers specific to each of two cell types:
- Cholinergic neurons -- implicated in disorders of memory and cognition
- Dopaminergic neurons – implicated in psychosis and movement disorders
2. The development and application of new, non-invasive methods based on positron emission tomography (PET)to image receptors and other markers in the human brain.
Published Articles or Reviews
Evaluation of [18F]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies.
Kramer V, Brooks AF, Haeger A, Kuljis RO, Rafique W, Koeppe RA, Raffel DM, Frey KA, Amaral H, Scott PJH, Riss PJ. ACS Chem Neurosci. 2020 Feb 5;11(3):427-435. doi: 10.1021/acschemneuro.9b00639. Epub 2020 Jan 15.
Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline.
Zhou Z, Müller MLTM, Kanel P, Chua J, Kotagal V, Kaufer DI, Albin RL, Frey KA, Bohnen NI. Neurology. 2020 Jan 28;94(4):e376-e383. doi: 10.1212/WNL.0000000000008683. Epub 2019 Nov 15.
Effects of plasma glucose levels on regional cerebral 18F-fluorodeoxyglucose uptake: Implications for dementia evaluation with brain PET imaging.
Viglianti BL, Wale DJ, Ma T, Johnson TD, Bohnen NI, Wong KK, Ky C, Frey KA, Townsend DM, Rubello D, Gross MD. Biomed Pharmacother. 2019 Apr;112:108628. doi: 10.1016/j.biopha.2019.108628. Epub 2019 Feb 20.
For a complete list, visit https://www.ncbi.nlm.nih.gov/pubmed/?term=Frey+Kirk%5BAuthor%5D